A Review of the Structure-Activity Relationship of Natural and Synthetic Antimetastatic Compounds.

There are innumerable anticancer compounds derived from either natural or synthetic origins. Many of these compounds have been further developed through structural modifications to not only inhibit cancer cell growth but also to exert an antimetastatic effect. This is achieved by attaching different substituents to generate different structure-activity relationships.

Inactivation of nuclear factor κB by MIP-based drug combinations augments cell death of breast cancer cells.

Background: Drug combination therapy to treat cancer is a strategic approach to increase successful treatment rate. Optimizing combination regimens is vital to increase therapeutic efficacy with minimal side effects.

Materials And Methods: In the present study, we evaluated the in vitro cytotoxicity of double and triple combinations consisting of 1'S-1'-acetoxychavicol acetate (ACA), (MIP) and cisplatin (CDDP) against 14 various human cancer cell lines to address the need for more effective therapy.

Anti-proliferative, apoptotic induction, and anti-migration effects of hemi-synthetic 1'-1'-acetoxychavicol acetate analogs on MDA-MB-231 breast cancer cells.

Nine analogs of 1'-1'-acetoxychavicol acetate (ACA) were hemi-synthesized and evaluated for their anticancer activities against seven human cancer cell lines. The aim of this study was to investigate the anti-proliferative, apoptotic, and anti-migration effects of these compounds and to explore the plausible underlying mechanisms of action. We found that ACA and all nine analogs were non toxic to human mammary epithelial cells (HMECs) used as normal control cells, and only ACA, 1'-acetoxyeugenol acetate (AEA), and 1'-acetoxy-3,5-dimethoxychavicol acetate (AMCA) inhibited the growth of MDA-MB-231 breast cancer cells with a half-maximal inhibitory concentration (IC) value of <30.